Summary of clinical development of drug candidates targeting chemokines
Neutralizing monoclonal antibodies unless otherwise noted.
| Chemokine | Company | Compound | Affinity | Indication | Clinical Phase | Status |
|---|---|---|---|---|---|---|
| pM | ||||||
| CCL2 | Millennium | ABN-912 | NA | RA | II | No efficacy |
| CCL2 | Centocor | CNTO 888 | 22 | Cancer | I | Ongoing |
| CCL2a | Noxxon | NOX-E36a | NA | Diabetic nephropathy | II | Ongoing |
| CXCL8 | Abgenix | ABX-IL8 | NA | Psoriasis | II | No efficacy |
| CXCL8 | Anogen | ABCream | NA | Psoriasis | Marketed in China | |
| CXCL10 | Medarex | MDX-1100 | NA | Ulcerative colitis | II | Ongoing |
| Rheumatoid arthritis | II | Ongoing | ||||
| CXCL12a | Noxxon | NOX-A12 | NA | Multiple myeloma, CLL | II | Ongoing |
CLL, chronic lymphocytic leukemia; NA, not available.
↵a Oligonucleotide.